

## A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** Not specified

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- age 9 to <21 years - recently diagnosed with T1D and can start the treatment phase within 6 months of diagnosis - body weight more than 66 pounds - fully vaccinated for age and willing to avoid certain live vaccines during the study - able to read and understand English or Spanish - use only insulin to control blood sugar (no other glucose-lowering medicines) - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Inclusion criteria

---

**Exclusion Criteria:**

- history of serious bacterial, viral, fungal, or other infections or current active infection - history of underlying heart disease - history of cancer other than of skin - severe allergy to milk or adhesives - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

**Interventions:**

Drug: Adalimumab, Drug: Anti-thymocyte globulin (ATG), Drug: verapamil extended-release capsule

**Conditions:**

Diabetes & Endocrine

**Keywords:**

T1D, Type 1 Diabetes

### More Information

**Description:** This study is looking at if we give ATG followed by either adalimumab or verapamil if those combinations will help in preserving insulin secretion 2 years after newly diagnosed type 1 diabetes.

**Study Contact:** Veronica Jones-Carr - [jone2678@umn.edu](mailto:jone2678@umn.edu)

**Principal Investigator:** Antoinette Moran

**Phase:** PHASE1

**IRB Number:** STUDY00025666

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.